NLRP3 and Cognitive impairment: To testify this hypothesis, we employed a selective small-molecular inhibitor (MCC950) of the NLRP3 inflammasome signaling to inhibit inflammasome activation and revealed that MCC950 treatment significantly prevented Aβ deposition and alleviated the cognitive impairments induced by HSV-1 infection.